Falling Chimerism after Reduced Intensity Conditioning Transplantation  by Alyea, Edwin P.
CLINICAL CHALLENGE1083-8791
doi:10.101
292Falling Chimerism after Reduced Intensity Conditioning
TransplantationA 54-year-old man with acute myelogenous leukemia (AML) in second complete remission received a re-
duced-intensity conditioning (RIC) stem cell transplant using fludarabine and intravenous busulfan. The
donor was an 8/8 HLA-A, -B, -C, and -DRB1 matched unrelated male. Graft-versus-host disease (GVHD)
prophylaxis was antithymocyte globulin, tacrolimus, and methotrexate (MTX) 5 mg/m2 on days 1, 3, 6, and
11, with a plan to taper tacrolimus by 30% at day 60, 30% on day 120, and discontinue at 6 months after trans-
plantation. His tacrolimus was tapered at day 60 as planned.
Evaluation at 4 months after transplantation demonstrated a slightly hypocellular marrow with no evidence of
recurrent disease by eithermorphology or cytogenetics.His counts are normal, and he has no evidence of acute
or chronic GVHD (aGVHD, cGVHD). Tacrolimus level at this time is 2.1 ng/mL. Serial chimerism studies
show:
% Donor in Peripheral Blood
Time Point Unfractionated CD31
2 months 90% 60%
4 months 60% 40%/10/162-0017$36.00/0
6/j.bbmt.2008.05.012What would you recommend?
 Continued taper of immune suppressive therapy as scheduled
 Rapid taper or discontinuation of immune suppressive therapy
 Donor lymphocyte infusion
 Increase immune suppressive therapy
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TransplantationREADER RESPONSES
In a recent issue of the ASBMT eNEWS, readers
were presented with the above Clinical Challenge
and invited to use an online poll to recommend a course
of treatment. The reader recommendations for ther-
apy were:
 83% Rapid taper or discontinuation of immune
suppressive therapy
 10% Donor lymphocyte infusion
 8%Continued taper of immune suppressive therapy
as scheduled
 0% Increase immune suppressive therapyCOMMENTARY
This case highlights several issues regarding the im-
portance of falling chimerism posttransplant and possi-
ble therapeutic interventions to reverse it.Thefirst issueis whether the fall in donor chimerism reflects graft re-
jection, the presence of recurrent disease, or both.
Some studies have demonstrated that mixed chimerism
more commonly occurs early after reduced intensity
conditioning (RIC) in patients with myelogenous dis-
ease compared with patients with lymphoid diseases
[1]. It is not clear whether the achievement of high levels
of donor chimerism after transplantation is related to
the patient’s disease, pretransplant treatment, or the in-
tensity of therapy received for conditioning. Studies
have demonstrated that ‘‘low’’ degrees of donor chime-
rism early after transplantation are associated with
decreased progression-free survival (PFS) in patients
with myeloid diseases [2,3]. Specifically, T cell chime-
rism of\50% is associated with a higher relapse rate
[2]. Serial chimerism analyses showing falling chime-
rism in patients with AML may also predict relapse
[4]. I would be worried about impending relapse in
this patient despite the recent study showing normal
morphology and cytogenetics.
There is general agreement that falling chimerism
requires intervention. The majority of respondents
Clinical Challenge 293(83%) recommended a rapid taper or discontinuation
of immune suppressive therapy. Although this would
be the course I would recommend, the rate of taper in
patients with unrelated or HLA-mismatched donors
is often more measured because of the concern for de-
veloping severe GVHD. Continuing with the original
taper schedule was recommended by about 8% of
respondents, but in many cases the clinical result is un-
satisfactory, with patients eventually relapsing. Once
off immune-suppressive therapy, donor lymphocyte
infusion (DLI) is often pursued as a next step, with
only partial success in reversing mixed chimerism [5].
It is not clear that other strategies such as prophylactic
DLI while on immune suppressive therapy, as sug-
gested by 10% of those responding, will reverse the
fall in chimerism. No one voted to increase immune
suppressive therapy.
Although high levels of donor chimerism are asso-
ciated with an improved outcome in patients with
AML, the best method to achieve high levels early after
transplantation and maintain them is under investiga-
tion.Whethermaintaining high levels of donor chime-
rism or reversing falling chimerism results in improved
disease control remains unproved, although the close
relationship between donor chimerism and outcome
in myelogenous diseases suggests that there is a com-mon hematopoietic target of the graft-versus-leukemia
reaction.
Edwin P. Alyea
Dana-Farber Cancer Institute, Boston, MassachusettsREFERENCES
1. Mohty M, Avinens O, Faucher C, Viens P, Blaise D, Eliaou JF.
Predictive factors and impact of full donor T-cell chimerism after
reduced intensity conditioning allogeneic stem cell transplanta-
tion. Haematologica. 2007;92:1004-1006.
2. Baron F, Maris MB, Sandmaier BM, et al. Graft-versus-tumor
effects after allogeneic hematopoietic cell transplantation with
nonmyeloablative conditioning. J Clin Oncol. 2005;23:1993-2003.
3. Alyea EP, Kim HT, Ho V, et al. Impact of conditioning regimen
intensity on outcome of allogeneic hematopoietic cell trans-
plantation for advanced acute myelogenous leukemia and myelo-
dysplastic syndrome. Biol Blood Marrow Transplant. 2006;12:
1047-1055.
4. HuismanC, deWegerRA, deVriesL,TilanusMG,VerdonckLF.
Chimerism analysis within 6months of allogeneic stem cell trans-
plantation predicts relapse in acute myeloid leukemia. Bone
Marrow Transplant. 2007;39:285-291.
5. Bethge WA, Hegenbart U, Stuart MJ, et al. Adoptive immuno-
therapy with donor lymphocyte infusions after allogeneic hema-
topoietic cell transplantation following nonmyeloablative
conditioning. Blood. 2004;103:790-795.
